Gas-sensing capsule takes another big step from lab to commercialisation

An ingestible gas-sensing capsule that provides real-time insights into gut health has moved closer to market with RMIT University transferring IP ownership to medical device company Atmo Biosciences.

In an announcement today, RMIT transferred all patents and associated intellectual property related to the Atmo Gas Capsule to Atmo in exchange for an equity stake in the company.

The innovative technology measures gaseous biomarkers directly at the source of production throughout the gut.

These biomarkers are used to measure gut transit time to aid diagnosis of common motility disorders such as gastroparesis and slow transit constipation.

Functional gut disorders like these impact 2 in 5 people.

Originally developed through ground-breaking research at RMIT, the ingestible gas-sensing capsule was licensed by Atmo in 2018.

Since then, the company has advanced the technology from concept to clinical reality – developing, manufacturing and trialling the device to create a market-ready solution for diagnosing gastrointestinal disorders.

Atmo Biosciences CEO Mal Hebblewhite said it was a significant milestone for both partners.

"Having RMIT as a strategic shareholder reinforces our shared commitment to bringing this innovative technology to market,” he said.

“Full ownership of our core IP further strengthens Atmo’s position as we advance toward regulatory clearance and commercialisation, ensuring long-term value for our company and the patients we aim to serve."

The assignment marks a significant step in Atmo’s commercialisation journey as it seeks regulatory clearance with the U.S. Food and Drug Administration (FDA).

This follows last year's successful completion of a pivotal clinical study demonstrating the safety and efficacy of the device on more than 200 subjects from 12 trial sites in the US and Australia

Earlier, the Atmo gas-sensing capsule was also used in a range of trials, such as one by Florida State University researchers to assess the impact of a restricted eating diet on gut gases and time taken for food to pass through the system.

Distinguished Professor Calum Drummond with Mal Hebblewhite at RMIT University.

Atmo Biosciences’ Head of Clinical Affairs Kyle Berean said that the trial demonstrated the potential applicability of the Atmo Gas Capsule beyond diagnostic applications.

“The Atmo Gas Capsule provides insights into gastrointestinal function including key markers such as regional gut hydrogen concentration and gastrointestinal transit time.”

“This information is useful not only to clinicians to aid diagnosis of gastrointestinal disorders, such as dysmotility, but can also be used by researchers to determine the impact and efficacy of dietary and pharmacological interventions,” said Berean, who helped invent the device at RMIT and joined Atmo to bring it to market.

Collaboration driving innovation

Distinguished Professor Calum Drummond AO, Deputy Vice-Chancellor Research and Innovation and Vice-President at RMIT University, said today’s agreement exemplified the university’s mission to translate academic research for social benefit.

“The equity component of this agreement strengthens our long-term collaboration, aligning our interests as Atmo continues to expand its platform technology."

“We are particularly proud that several of our students and early career researchers played instrumental roles in developing this technology at RMIT and have continued to contribute as co-founders at Atmo Biosciences,” Drummond said.

Hebblewhite said Atmo’s vision is to improve the quality of life for the many sufferers of common and debilitating gastrointestinal disorders and diseases, providing clinicians and researchers with tools that deliver actionable insights regarding gastrointestinal dysfunction.

“Much about the gut remains a mystery, and this device allows us to shine a light for better understanding of what is happening in this critical part of our body for timely diagnosis, monitoring, and insight” he said.

The Atmo Gas Capsule System is pending FDA 510(k) clearance and is not available for sale. The Atmo Gas Capsule System is an investigational device exclusively for use in clinical research.

Story: Michael Quin

Health

15 April 2025

Return to RMIT News

Health

15 April 2025

Research
STEM
Industry
Science and technology

Engage

Contact RMIT News

Find an expert

Study with us

Research at RMIT

Related News

Quantum battery device lasts much longer than previous demonstrations

Researchers from RMIT University and CSIRO, Australia’s national science agency, have unveiled a method to significantly extend the lifetime of quantum batteries – 1,000 times longer than previous demonstrations.

Sea urchin cull could deliver $92 million in ecosystem benefits: study

Restoring Port Phillip Bay’s dwindling kelp forests by culling overgrazing sea urchins would deliver more than $92 million in benefits, a new study has found.

RMIT MedTech invention goes to market

An ingestible gas-sensing capsule invented at RMIT to provide real-time insights into gut health is now cleared for use in the United States.

Bushfire evacuation simulator wins prestigious US prize

A collaboration spanning Europe, Australia and North America to create a cutting-edge bushfire evacuation simulator has been recognised for its contribution to fire safety.

Acknowledgement of Country

RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business - Artwork 'Sentient' by Hollie Johnson, Gunaikurnai and Monero Ngarigo.

More information

Gas-sensing capsule takes another big step from lab to commercialisation